Mirum Pharmaceuticals
MIRM
51 hedge funds and large institutions have $361M invested in Mirum Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 8 closing their positions.
11% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 19
0.29% less ownership
Funds ownership: 74.08% → 73.79% (-0.29%)
1% less capital invested
Capital invested by funds: $366M → $361M (-$4.84M)
12% less funds holding
Funds holding: 58 → 51 (-7)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
88% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$4.3M |
| 2 |
Axa
Paris,
France
|
+$1.31M |
| 3 |
Charles Schwab
San Francisco,
California
|
+$926K |
| 4 |
Invesco
Atlanta,
Georgia
|
+$769K |
| 5 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
+$609K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$4.73M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.9M |
| 3 |
Morgan Stanley
New York
|
-$1.16M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$824K |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$651K |
MIRM Hedge Fund Activity: Q3 2020 in Review
51 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q3 2020, worth a combined $361M — down 1.3% from $366M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of MIRM and 1 opened new positions — a net loss of 7 holders — while 19 trimmed existing stakes and 21 added.
The largest buyer was Millennium Management, adding an estimated $4.3M. The largest seller was Sofinnova Investments, cutting an estimated $4.73M.
- 51 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q3 2020, down from 58 in Q2 2020.
- Funds reported $361M of Mirum Pharmaceuticals stock for Q3 2020, down 1.3% quarter-over-quarter.
- 1 fund opened new Mirum Pharmaceuticals positions in Q3 2020 and 8 closed out, a net change of -7 holders.
- The largest Mirum Pharmaceuticals buyer in Q3 2020 was Millennium Management, an estimated $4.3M added.
- The largest Mirum Pharmaceuticals seller in Q3 2020 was Sofinnova Investments, an estimated $4.73M sold.
Based on aggregated 13F filings for Q3 2020.